Recurrent visceral leishmaniasis relapses in HIV co-infected patients are characterized by less efficient immune responses and higher parasite load

Visceral leishmaniasis (VL) and HIV co-infection (VL/HIV) has emerged as a signif-icant public health problem in Ethiopia, with up to 30% of patients with VL co-infected with HIV. These patients suffer from recurrent VL relapses and increased mortality. Those with a previous history of VL relapses (recurrent VL/HIV) expe-rience increased VL relapses as compared to patients with HIV presenting with their first episode of VL (primary VL/HIV). Our aim was to identify drivers that ac-count for the higher rate of VL relapses in patients with recurrent VL/HIV (n = 28) as compared to primary VL/HIV (n = 21). Our results show that the relapse-free survival in patients with recurrent VL/HIV was shorter, that they had higher para-site load, lower weight gain, and lower recovery of all blood cell lineages. Their poorer prognosis was characterized by lower production of IFN-gamma, lower CD4(+) T cell counts, and higher expression of programmed cell death protein 1 (PD1) on T cells.

Automated summary

Visceral leishmaniasis (VL) and HIV co-infection (VL/HIV) is a significant public health problem in Ethiopia, with up to 30% of VL patients co-infected with HIV. Patients with recurrent VL/HIV have a higher rate of VL relapses compared to those with primary VL/HIV. Poor prognosis in recurrent VL/HIV patients is characterized by shorter relapse-free survival, higher parasite load, lower weight gain, lower recovery of blood cell lineages, lower production of IFN-gamma, lower CD4(+) T cell counts, and higher expression of PD1 on T cells.